Weiss Ratings Reiterates “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

4D Molecular Therapeutics (NASDAQ:FDMT)‘s stock had its “sell (d-)” rating restated by Weiss Ratings in a report released on Tuesday,Weiss Ratings reports.

Other equities research analysts also recently issued research reports about the company. Barclays lowered their price target on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a research report on Friday, May 9th. Chardan Capital reiterated a “buy” rating and issued a $25.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, July 3rd. Finally, The Goldman Sachs Group cut their price target on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.56.

4D Molecular Therapeutics Price Performance

NASDAQ FDMT opened at $4.41 on Tuesday. The company’s 50 day simple moving average is $4.13 and its two-hundred day simple moving average is $4.04. The stock has a market capitalization of $204.32 million, a PE ratio of -1.39 and a beta of 2.81. 4D Molecular Therapeutics has a 1 year low of $2.23 and a 1 year high of $18.14.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative net margin of 767,126.06% and a negative return on equity of 33.26%. On average, research analysts anticipate that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently modified their holdings of the stock. Millennium Management LLC boosted its stake in shares of 4D Molecular Therapeutics by 1,607.1% during the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after purchasing an additional 1,337,497 shares in the last quarter. BNP Paribas Financial Markets bought a new stake in 4D Molecular Therapeutics during the fourth quarter worth about $532,000. Two Sigma Investments LP boosted its stake in 4D Molecular Therapeutics by 196.3% during the fourth quarter. Two Sigma Investments LP now owns 313,993 shares of the company’s stock worth $1,749,000 after acquiring an additional 208,021 shares in the last quarter. Harbor Capital Advisors Inc. bought a new stake in 4D Molecular Therapeutics during the first quarter worth about $99,000. Finally, Vanguard Group Inc. boosted its stake in 4D Molecular Therapeutics by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 2,860,508 shares of the company’s stock worth $15,933,000 after acquiring an additional 92,791 shares in the last quarter. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.